| Identification | Back Directory | [Name]
CTX0294885 | [CAS]
1439934-41-4 | [Synonyms]
CS-1944
CS-1885
CTX0294885
CTx0294885, >99%
CTX-0294885, >=98%
CTX-0294885; CTX 0294885; CTX0294885; CTX 0294885.
2-(5-chloro-2-(4-(piperazin-1-yl)phenylaMino)pyriMidin-4-ylaMino)-N-MethylbenzaMide
2-[[5-Chloro-2-[[4-(1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methylbenzamide
Benzamide, 2-[[5-chloro-2-[[4-(1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl-
2-(5-chloro-2-(4-(piperazin-1-yl)phenylamino)pyrimidin-4-ylamino)-N-methylbenzamide CTX0294885 | [Molecular Formula]
C22H24ClN7O | [MDL Number]
MFCD28137930 | [MOL File]
1439934-41-4.mol | [Molecular Weight]
437.93 |
| Chemical Properties | Back Directory | [density ]
1.332±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
≥21.9 mg/mL in DMSO; insoluble in EtOH; insoluble in H2O | [form ]
solid | [pka]
14.57±0.46(Predicted) | [color ]
Light yellow to green yellow | [InChIKey]
FCLOIQHNUARDSR-UHFFFAOYSA-N | [SMILES]
C(NC)(=O)C1=CC=CC=C1NC1C(Cl)=CN=C(NC2=CC=C(N3CCNCC3)C=C2)N=1 |
| Hazard Information | Back Directory | [Uses]
CTX-0294885 is a broad spectrum kinase inhibitor that can capture 235 kinases from MDA-MB-231 cells, and can capture all members of the AKT family. CTX-0294885 is a powerful reagent for analysis of kinome signaling networks that can be used for the research of diseases like inflammation, diabetes, and cancer[1]. | [Biological Activity]
ctx-0294885 is a novel bisanilino pyrimidine. it has inhibitory activity towards a wild range of kinases in vitro. ctx-0294885 is capable of capturing more than half of the expressed kinome in mda-mb-231 cells. large-scale ctx-0294885-based affinity purification with lc?ms/ms identifies 235 protein kinases. ctx-0294885 binds additional kinases that were not identified from previous studies using other kinase capture reagents. it is further developed into a sepharose-supported kinase capture reagent. ctx-0294885 is a new tool for analysis of kinome signaling networks. [1] | [Synthesis]
The reaction was carried out with 2-((2,5-dichloropyrimidin-4-yl)amino)-N-methylbenzamide (149 mg, 0.503 mmol) and 4-(piperazin-1-yl)aniline hydrochloride (134 mg, 0.627 mmol) as raw materials and stirred for 16 hr at 95 °C in the presence of 2,2,2-trifluoroethanol (5 mL) and concentrated aqueous hydrochloric acid solution (2 drops). Upon completion of the reaction, the mixture was cooled to room temperature, diluted with 5% aqueous sodium hydroxide solution (100 mL) and subsequently extracted with ethyl acetate (3 x 100 mL). The organic phases were combined, washed with saturated saline, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. Purification by reversed-phase column chromatography (12 g C18 column, 0-40% acetonitrile/methanol gradient elution) afforded the crude product was washed with dichloromethane (2 × 2 mL) and dried to afford the target compound 2-((5-chloro-2-((4-(piperazin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)-N-methylbenzamide (33.4 mg, 15% yield) as an off-white solid.1H NMR (400 MHz, d6-DMSO) δ 9.19 (s, 1H), 8.78-8.71 (m, 2H), 8.15 (s, 1H), 7.74 (dd, J = 7.8, 1.3 Hz, 1H), 7.49-7.42 (m, 3H), 7.12 (t, J = 7.2 Hz, 1H), 6.86 ( d, J = 9.0 Hz, 2H), 3.00-2.95 (m, 4H), 2.86-2.79 (m, 7H).LCMS: retention time 4.28 min; m/z 438.1 [M + H]+. | [References]
1. zhang l, holmes ip, hochgr?fe f et al. characterization of the novel broad-spectrumkinase inhibitor ctx-0294885 as an affinity reagent for mass spectrometry-basedkinome profiling. j proteome res. 2013 jul 5;12(7):3104-16. |
|
|